Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;44(2):414-423.
doi: 10.1111/ijlh.13763. Epub 2021 Nov 16.

Guidance for establishing a factor VIII testing protocol for the myriad of factor VIII products

Richard A Marlar  1 , Jana N Gausman  2 , Marian A Rollins-Raval  1
Affiliations

Guidance for establishing a factor VIII testing protocol for the myriad of factor VIII products

Richard A Marlar et al. Int J Lab Hematol. 2022 Apr.

Abstract

Introduction: Management of hemophilia A has changed significantly in the past few years with the expansion of new and/or modified products as treatment options. Unfortunately, many of the standard factor VIII assays do not always accurately measure all available treatment products; therefore, the laboratory must investigate various assay algorithms to ensure the reporting of the correct results.

Methods: Requirements for factor testing, diagnosis and severity levels, product testing, factor VIII inhibitor detection and titers, are evaluated, and potential algorithms are created for optimal assessment of patients with hemophilia A.

Results: The potential for inaccurate result reporting for patients with hemophilia A or those being treated with the myriad of products has left many laboratories uncertain as to which assay algorithm to implement to ensure reporting the correct results for all products used in their hemophilia program. Algorithms for using either One-stage Clotting assays or Chromogenic assays or a combination of both types of assays are presented for each laboratory to implement based on their clinical situation.

Conclusions: Several algorithms are considered based on the needs of the clinical providers and their patients. Each laboratory must select a testing algorithm that is cost-effective and within available resources, yet that encompasses the needs of their providers and patients. Laboratory personnel must consider all assay uses (factor VIII levels, different products, interfering products, and inhibitor titers) in determining the best algorithm for their laboratory. This paper is a starting guide for developing the best factor VIII testing assays and protocols for your laboratory.

Keywords: chromogenic assays; clotting assays; factor VIII; factor VIII inhibitors; hemophilia A.

PubMed Disclaimer

References

REFERENCE

    1. Lee C, Berntorp E, Hoots W. Textbook of Hemophilia, 2nd ed. Blackwell Publishing Ltd; 2010.
    1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1-e47.
    1. Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:1935-1939.
    1. Van den Bossche D, Peerlinck K, Jacquemin M. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement. Int J Lab Hematol. 2018;40(Suppl 1):21-29.
    1. Marlar RA, Strandberg K, Shima M, Adcock-Funk D. Clinical utility and impact of the use of the chromogenic versus one-stage factor activity assays in hemophilia A and B. Eur J Hemat. 2019;103:3-14.

LinkOut - more resources